Betta Pharmaceuticals

C4 Therapeutics Ends Cancer Trial, Awaits Betta Funds

C4 Therapeutics Halts Cancer Project Post Phase 1/2 Trial Setback

Anika Sharma

C4 Therapeutics has made a strategic decision to discontinue the development of CFT8634, an oral BRD9 degrader, following a phase ...